Choose a model
Each card values Humacyte a different way, shown at our starting inputs. Pick one to see and change how it works.
Set your assumptions
Humacyte on revenue: sales per share grow and the stock trades at a normal price-to-sales multiple. For companies not yet profitable.
Years to project
Growth of revenue per share
Revenue per share; not enough history; starts at 5%
Exit P/S
Starts at its own median P/S over five years
Your desired return
Margin of safety
More
Your buy price
The expected return is measured from it; starts at today's price
How it's worked out
Today's revenue per share
Last twelve months
$0.01
Revenue in 2031
Grows 5.0% a year for 5 years
$0.01
Price in 2031
$0.01 × 15.0 P/S
$0.15
Worth today
÷ 1.10^5: your 10% a year, taken back out
$0.09
Fair value
The most you can pay and still earn 10% a year
$0.09
Buy below
Fair value minus your 25% margin of safety
$0.07
Paying $0.45 instead gives -20.1% a year. Every rule is on the methodology page.
Outcome
What your assumptions give, and the path from today's price.
Fair value
$0.09
Expected return
-20.1% a year
Future price, 2031
$0.15
Buy below
$0.07
Price 396% above fair valuePrice $0.45, at your 10% return
Projection
Solid blue: the price at each year end. Dashed blue: from today's price to the 2031 price. Green: from the fair value, rising at your 10% a year to the same end point; buy at or below it and you earn at least that. Every rule is on the methodology page. A model, not a forecast or advice.
Humacyte (HUMA) intrinsic value and fair value
The calculator grows one of Humacyte's per-share figures (earnings, free cash flow, revenue, book value or dividends) for a few years, puts an exit multiple on it, and discounts the result back at the yearly return you want. The answers below use its starting inputs for HUMA; this is analysis, not investment advice.
Frequently asked
What is Humacyte's (HUMA) intrinsic value?+
With Intrinsiqq's starting inputs, Humacyte's fair value is about $0.09 a share, based on its revenue per share. That assumes revenue per share of $0.01 grows about 5.0% a year for 5 years, the stock then trades at 15.0 times revenue, and you want a 10.0% yearly return. Every input can be changed on the page; the result is a model, not a forecast.
Is Humacyte overvalued?+
At $0.45, the price is 396% above that fair value of $0.09, and buying at today's price would return about -20.1% a year if those inputs hold. Whether that is cheap or dear depends on whether you believe the growth and the exit multiple, which is what the calculator lets you test. This is analysis from SEC filings, not investment advice.
What growth does the Humacyte valuation assume?+
Revenue per share grows about 5.0% a year to start, a default, because there is too little history. The exit multiple starts at its own median over five years.
What is a good margin of safety for Humacyte?+
A margin of safety is the cushion you want below the fair value before buying, in case the inputs are wrong. The calculator uses 25%, which puts the buy-below price at $0.07. Less predictable businesses deserve a wider cushion, or a higher desired return.
Peers
Biological Products, (No Diagnostic Substances) · Pick stocks to compare with HUMA
Held by ETFs
HUMA is in 4 US ETFs. The largest of them, with HUMA's weight in each:
Spot a number that looks wrong? Check it in HUMA's SEC filings or
Download this analysis as a PDF (Pro)
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Keep analysing HUMA
Create a free account and get 14 days of Premium: every stock and every tool.
- Unlimited stocks
- Stock screener
- Portfolio tracker
- Editable DCF
- Compare side by side
- Unlimited alerts
No card. Moves to Free after, unless you upgrade.
Already have an account?
Or come back tomorrow. Stocks on your watchlist are always free to view.